[Advances in gastrointestinal peptides: somatostatin].
Twenty years after being identified as "somatotropin release inhibiting factor" (SRIF) and "growth-hormone release inhibiting hormone" (GH-RIH), under a new name, somatostatin (SMS) has reached an outstanding position in gastroenteropancreatic endocrinology. It is a powerful and universal inhibitor of the digestive functions: secretion, motility, absorption and splanchnic blood flow. Long-acting synthetic analogues have made possible its therapeutic trial in certain clinical problems. This review covers the advances in several areas of interest for gastroenterologists: (a) the role of SMS in the regulation of digestive physiology and its participation in neurohumoral and inmunoneuropeptidic interrelations; (b) in relation to gastric acid secretion, hypotheses on supposed links between duodenal ulcer and Helicobacter pylori infection; (c) theoretical and experimental bases for somatostatin analogues use in the treatment of bleeding esophageal varices; (d) current status of the management of other nonneoplastic gastroenteropancreatic diseases; and (d) strategy for the therapy of endocrine tumors of the digestive system.
Ubilluz
R
R
Universidad Nacional Mayor de San Marcos, Lima, Peru.
D004064:Digestive System / Q000187:drug effects; D004068:Digestive System Physiological Phenomena; D005767:Gastrointestinal Diseases / Q000188:drug therapy / Q000503:physiopathology; D006801:Humans; D015213:Neuroimmunomodulation / Q000187:drug effects; D013004:Somatostatin / Q000494:pharmacology / Q000502:physiology* / Q000627:therapeutic use
D013004:Somatostatin
Avances en peptidos gastrointestinales: somatostatina.